ABSTRACT
Background Testing programs have been utilized as part of SARS-CoV-2 mitigation strategies on university campuses, and it is not known which strategies successfully identify cases and contain outbreaks.
Objective Evaluation of a testing program to control SARS-CoV-2 transmission at a large university.
Design Prospective longitudinal study using remote contactless enrollment, daily mobile symptom and exposure tracking, and self-swab sample collection. Individuals were tested if the participant was (1) exposed to a known case, developed new symptoms, or reported high-risk behavior, (2) a member of a group experiencing an outbreak, or (3) at baseline upon enrollment.
Setting An urban, public university during Autumn quarter of 2020
Participants Students, staff, and faculty.
Measurements SARS-CoV-2 PCR testing was conducted, and viral genome sequencing was performed.
Results We enrolled 16,476 individuals, performed 29,783 SARS-CoV-2 tests, and detected 236 infections. Greek community affiliation was the strongest risk factor for testing positive. 75.0% of positive cases reported at least one of the following: symptoms (60.8%), exposure (34.7%), or high-risk behaviors (21.5%). 88.1% of viral genomes (52/59) sequenced from Greek-affiliated students were genetically identical to at least one other genome detected, indicative of rapid SARS-CoV-2 spread within this group, compared to 37.9% (11/29) of genomes from non-Greek students and employees.
Limitations Observational study.
Conclusion In a setting of limited resources during a pandemic, we prioritized testing of individuals with symptoms and high-risk exposure during outbreaks. Rapid spread of SARS- CoV-2 occurred within outbreaks without evidence of further spread to the surrounding community. A testing program focused on high-risk populations may be effective as part of a comprehensive university-wide mitigation strategy to control the SARS-CoV-2 pandemic.
Competing Interest Statement
H.Y.C. has served as a consultant for Merck and GlaxoSmithKline and has received research funding from Sanofi Pasteur and research support from Cepheid, Genentech and Ellume. G. S. G. has received research grants and research support from the NIH, UW, the Bill & Melinda Gates Foundation, Gilead Sciences, Alere Technologies, Merck & Co, Janssen Pharmaceutica, Cerus Corporation, ViiV Healthcare, Bristol-Myers Squibb, Roche Molecular Systems, Abbott Molecular Diagnostics, and TheraTechnologies/TaiMed Biologics, Inc.
Funding Statement
This study was funded by the United States Senate and House of Representative Bill 748, Coronavirus Aid, Relief, and Economic Security Act. The funding source had no role in the study design, conduct, or reporting.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of Washington Institutional Review Board approved this study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data and code used for analyses may be available upon request.
